Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Share-based Compensation (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Share-based Compensation for 17 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 74.31% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.2 million through Dec 2025, down 29.32% year-over-year, with the annual reading at $35.2 million for FY2025, 29.32% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.8 million at Myriad Genetics, down from $12.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $14.5 million in Q2 2024, with the low at $2.8 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $10.0 million, with a median of $10.2 million recorded in 2022.
  • The sharpest move saw Share-based Compensation surged 60.0% in 2024, then crashed 74.31% in 2025.
  • Over 5 years, Share-based Compensation stood at $8.4 million in 2021, then fell by 2.38% to $8.2 million in 2022, then increased by 26.83% to $10.4 million in 2023, then rose by 4.81% to $10.9 million in 2024, then plummeted by 74.31% to $2.8 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.8 million, $12.2 million, and $10.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.